MerLion Preps Finafloxacin For Phase III As Advantages Confirmed
This article was originally published in PharmAsia News
Executive Summary
Singapore-based MerLion is planning to take its lead development project, the antibiotic finafloxacin, into a Phase III program for urinary tract infections after Phase II results showed advantages over the current standard of care ciprofloxacin, along with rapid, broad activity and potential for the easy switching of patients from intravenous to oral dosing.